Daniel Elías Martín Herranz’s Post

🌟 Thrilled to share out latest peer-reviewed publication in collaboration with the University of Birmingham. In this open-label clinical trial, focused on chronic inflammation, we show that our new InflammAge biomarker is actionable, can stratify patients and captures the effects of intervention better than other traditional inflammation markers (like CRP). There is still a lot of work to do to further validate this discovery, but it adds evidence to the opportunity to improve biological ageing in humans by leveraging robust biomarkers and novel interventions. Have a read here: https://lnkd.in/e3SYM46E #inflammation #nutraceuticals #biologicalage #longevity Kirsty C McGee Lisa Schmunk Janet Lord and many others

⏰ A new #epigenetic clock is in town! If you are interested in accessible #longevity biomarkers, please check our latest pre-print describing how we have built the world's first saliva-based biomarker for chronic #inflammation (one of the hallmarks of #ageing in humans) --> 🔥 InflammAge 🔥 https://lnkd.in/eJmguJg5 Furthermore, this framework can be generalised to build novel saliva-based and biologically-interpretable biomarkers for other #preventativehealthcare, #patientstratification and #drugdiscovery applications. Big thanks to all the Hurdle bio-infrastructure team, our collaborators and incredible scientists that have helped us push the boundaries of #ageing biomarkers! Hurdle Dr. Toby Call Dr. Hira Javaid Vanja Jovicevic Dragoljub Kojadinović Natacha Tomkinson Dr. Eliska Zlamalova Emma Stone Miloš Gavrilov Rob Thompson Tom Stubbs Tulane University School of Medicine Dr. Waylon Hastings The University of Edinburgh Generation Scotland Dr. Daniel McCartney Archie Campbell Professor Andrew McIntosh Professor Riccardo Marioni University of Birmingham Dr. Kirsty C McGee Dr. Jack Sullivan Dr. Thomas Jackson Professor Janet Lord Bayer | Consumer Health Karl Wishart Veronika Óvári, PharmD, PharmD Dr. Christian Behrens, PhD. RD., PhD. RD. CSSD. CSCS. and others ...

🏛 It was lovely to be back at the European Bioinformatics Institute | EMBL-EBI and celebrate "Fifty Years of Bioinformatics" with Professor Dame Janet Thornton (who supervised my PhD, some people call her the "grandmother of bioinformatics") and Roman Laskowski (and absolute legend in computational protein structure prediction). 🤩 I am honoured that Janet gave me the opportunity to speak at this symposium on the occasion of her retirement. I talked about #epigenetics and #biomarkers of #ageing, as well as my journey with Hurdle as a #startup founder. 👩🔬 I was inspired by the community of scientists that Janet has mentored over her incredible career (many whom I had the pleasure to share the lab with) as well as all the progress we have made in leveraging computational tools to understand protein structure, enzyme mechanisms and the biology of ageing. 💻 To many more years of #bioinformatics research! Handan Melike Donertas Linda Partridge Veronika Kedlian Dobril Ivanov Daniel Fabian António Ribeiro Cantin B. Neera Borkakoti Marcia Anahí Hasenahuer Jon Tyzack Sergio Martínez Cuesta Lorena Magraner Pardo and many more

🎉 I am thrilled to finally announce our strategic partnership with Bayer | Consumer Health. Since my academic times at the European Bioinformatics Institute | EMBL-EBI, I have been deeply passionate about empowering consumers with the latest science and data to achieve #healthyageing. It is imperative that we democratise access to the latest biomarker technologies, which have been 'hidden' in the lab for many years or only tried by a few #biohackers. This way we can really drive forwards preventative and personalised care. By merging our science and diagnostics infrastructure with Bayer's consumer expertise and distribution channels, this partnership will bring ageing #biomarkers and scientifically-backed interventions to the mainstream. The new saliva-based #BiologicalAge Test we have co-developed has been in the making for more than 2 years. With a focus on reproducibility, actionability and understanding better the molecular mechanisms that drive human ageing, we are now in a position to push the boundaries of what is possible with epigenetic and multi-omics data. Stay tuned since we will be publishing the pre-print backing up this work in the next weeks. Huge thank you to everyone at Hurdle and #teambayer that has been involved in making this partnership a reality. Given the different dynamics involved, it is not always easy to make startups and large corporates collaborate together effectively and move fast. But we made it happen. And we couldn't have asked for a more driven, passionate and fun team to get the job done. This is just the beginning! 🚀 Lisa Schmunk Leona Mc Girr Emma Stone Roughan Sheedy Richard Rilstone Ian Robinson Miloš Gavrilov Chuck Paiusi Pierric Descamps Ana Magalia David Russell MSc Hector Watson Gordon McCulloch Toby Call Rob Thompson Charles Ball Tom Stubbs Karl Wishart Aquil Harjivan Veronika Óvári, PharmD Christian Behrens, PhD. RD. CSSD. CSCS. Nicolas Mansali Lucía Montes Oviaño Melanie Wamsler Lucas Maciejewski Jeff Donald Bailu Lu Margaret Gryszkiewicz André J. Zila Florence Dupasquier Holger Lenz Karen Hackney David Evendon-Challis and many more #digitalhealth #precisionhealth #diagnostics #daas #biomarkers #biomarkerdiscovery #longevity

Back from #bioeurope2023 and I finally had some time to digest the conversations and insights from the conference. 🤖 #AI for drug discovery has reached the #pharma mainstream. --> Thomas Clozel from Owkin: "we need more data federation and data access to keep innovating". 👩💻 + 👨🔬 #techbio approaches are here to stay.  --> Dr. Matthias Müllenbeck, MBA from Merck Group: "pharma and biotech companies are actually data companies at heart (i.e. decision making based on (pre)clinical data on which assets get progressed/acquired). [Side note: Tom Stubbs and I were actually discussing that they are just a very special breed of #fintech if you take it to the next digitalisation step 🤔]. AI in pharma currently mainly being applied across insight generation (e.g. asset landscaping of therapeutic area and automatically monitor it), content generation (e.g. target identification, medical writing) and interactions (e.g. procurement bot)." --> VCs are finally starting to get the specific dynamics of techbio (spoiler alert: it is not tech, it is not biotech). 🤝 Partnerships between pharma and startups are becoming more common and streamlined. --> Isabelle Scarabin from Bayer: "We need open communication, trust and transparency between both parties. Furthermore, we have developed the concept of 'arms-length', where we give companies full autonomy while working closely with them. This ensures that the innovation culture in a startup is maintained while the pharma capabilities and channels are added." [Side note: having worked with Bayer for several years now, I can def say this mindset has worked really well for both sides]. Disclaimer: not exact quotes of those individuals, just what I understood the core of their argument was. Really cool to see the new partnership opportunities that we have identified for our #epigenetics and multi-omics biomarkers discovery engine + #daas insfrastructure. Thanks to everyone involved in facilitating those discussions! Maximilien Grandclaudon Roby Kanichay Joost (Johannes) van Heuveln Chris Vlahos Lori Badura Mark Paris Philipp Buchgraber Kam Dhaliwal Pedro Lima Angel Cebolla Ramirez Sandra Gavaldá Taylor Avei Jules Foster Cosmin Pocanschi Jake Hanks Ellen Zhang Ramakrishna Guduru Amanda Chen

Looking forwards to connecting with our #pharma colleagues in #bioeurope2023 next week. Using our AI-driven #biomarker discovery engine, we are already accelerating 3-10X the launch of novel #biomarkers for our partners (more info on the latest work on chronic inflammation we have done with Bayer in previous posts). #epigenetics #multiomics #machinelearning #techbio #daas

💥 The discovery of novel #companion #diagnostics for #oncology needs to be systematised and accelerated. My ex-EBI colleague Michael Menden has published a fantastic new tool (#OncoBird) in Nature Communications to get us closer to this. Using data from oncology randomised clinical trials (#RCTs), they are able to discover predictive response #biomarkers for #personalised treatment. If these biomarkers can then be regulated+packaged as companion diagnostics and deployed+distributed through diagnostics-as-a-service (#DaaS) infrastructure, this could tremendously benefit #cancer #patients. Also, I wonder if OncoBird would become more powerful using DNA methylation (#epigenetic) data? i.e. can we capture both genetic alterations and tumour subtype information using a single DNA methylation assay? Any #pharma partners with oncology pipelines (and oncology RCT molecular data / samples), please get in touch! URL to the paper: https://lnkd.in/er7TQrEf ********************************************************** A quick summary of the paper for the geeky ones 🤓 : 💡 There is a massive need to develop actionable biomarkers to personalise oncology treatment. 🔬 The authors have created the OncoBird framework, which analyses biomarker data (inc. genetic data) from RCTs to yield tumour subtype-specific biomarkers with treatment benefits. In other words, given genetic data from a tumour (hypothesis-free) and previous knowledge about tumour subtypes (hypothesis-driven, prior cancer biology knowledge), we want to identify biomarkers that predict higher chances of survival with a specific treatment vs alternative treatment (i.e. develop predictive response biomarkers). 🏥 They demonstrate the utility of this framework using data from the FIRE-3 trial: --> This includes metastatic colorectal cancer (mCRC) patients who were treated with FOLFIRI and either #cetuximab (Eli Lilly and Company / Merck Group) or #bevacizumab (Genentech).  --> Besides re-discovering known predictive biomarkers (like RAS or BRAF mutations associated with cetuximab resistance), OncoBird uncovers new ones (like ARFRP1 amplifications associated with longer survival in cetuximab vs bevacizumab in the CMS2 tumour subtype).   😍 This framework can be generalised to any RCT with molecular data, and allows for interpretability and transparency, which is key for clinical decision making. Huw Ricketts Richard Watts Tanya Aneichyk James Hadfield Martin Widschwendter Maria C. M. Orr Karl Wishart

There is nothing more exciting than seeing our products in action (and the #biomarker R&D + #DaaS proposition accelerating this for the end customer)! 😎 Alexey Strygin please tell us your #health optimisation secrets to get that #BioAge result, very impressive! Also, let me know if you are interested in hearing about our latest research on quantifying actionable chronic #inflammation using #epigenetic data 🔬 . New exciting stuff coming out of the door in the next months. So watch out this space! 🤓